Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023

OXFORD, England, October 16, 2023--Exscientia plc (Nasdaq: EXAI) today announced two abstracts to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24, 2023 in Madrid, Spain.

Related Keywords

Madrid ,Spain ,Sara Sherman ,European Society For Medical Oncology ,Nasdaq ,European Society ,Medical Oncology ,Professor Andrew Hopkins ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Relations Contact ,Precision Medicine ,Pml ,Exscientia ,Drug Candidates ,Patient Populations ,Osmo ,Preclinical Data ,Csd1 ,Potential ,Oncology Pipeline ,Cell Differentiation ,